United States (US)

IKB alpha peptide

Cat No. GTX27546

Application Blocking, Inhibition assay
Reactivity Human
Species Human

Application Note

Intended for use as a control peptide when used with anti-IkB alpha (C-terminal specific ab GTX27545) to block specific interaction of anti-IkB alpha (C-terminal specific) with the IkB alpha subunit. Control peptide should be used at 1.0 mg per 1.0 ml of antiserum per assay.




Preservative: 0.01% Sodium Azide; Constituents: 0.15M Sodium Chloride, 0.02M Potassium Phosphate. pH 7.2


Keep as concentrated solution. Store at 4ºC short term. For extended storage aliquot and store at -20ºC or below. Avoid freeze-thaw cycles.


1 mg/ml (Please refer to the vial label for the specific concentration.)

Antigen Species



For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.


Nfkb Inhibitor Alpha,Ikba,Mad-3,Nfkbi,Nfkbia

Cellular Localization



Three major forms of IkB-like molecules have been identified and each is characterized by multiple copies of ankyrin repeats. IkB-alpha and IkB-beta appear to be the major regulatory forms of IkB in most cells. These proteins interact with p65 or c-Rel containing forms of NFkB and block nuclear import by masking the nuclear localization sequences of NFkB. The activation of NFkB involves the inducible phosphorylation and subsequent degradation of IkB. Immunoblotting easily detects the hyper-phosphorylated forms of IkB-alpha, but not phosphorylated IkB-beta. Interestingly, IkB-alpha and IkB-beta mediate different NFkB responses. IkB-alpha appears to control more transient activation of NFkB in response to an inducer, while IkB-beta controls a persistent response. Bcl-3 interacts with p50 and p52 containing forms of NFkB, but rather than being an inhibitor it appears to function to stimulate transcription. The degradation of IkB is confirmed by immunoblotting.

Research Area

Package List Price ($)
$ 179